Current status and future strategies of cytoreductive surgery plus intraperitoneal hyperthermic chemotherapy for peritoneal carcinomatosis.
This article is to offer a concise review on the use of cytoreductive surgery (CRS) plus intraperitoneal hyperthermic chemotherapy (IPHC) for the treatment of peritoneal carcinomatosis (PC). Traditionally, PC was treated with systemic chemotherapy alone with very poor response and a median survival of less than 6 mo. With the establishment of several phase II studies, a new trend has been developed toward the use of CRS plus IPHC as a standard method for treating selected patients with PC, in whom sufficient cytoreduction could be achieved. In spite of the need for more high quality phase III studies, there is now a consensus among many surgical oncology experts throughout the world about the use of this new treatment strategy as standard care for colorectal cancer patients with PC. This review summarizes the current status and possible progress in future.
Al-Shammaa
Hassan-Alaa-Hammed
HA
Department of Oncology, Zhongnan Hospital of Wuhan University, Cancer Center of Wuhan University, and Hubei Cancer Clinical Study Center, No 169 Donghu Road, Wuchang District, Wuhan 430071, Hubei Province, China.
Li
Yan
Y
Yonemura
Yutaka
Y
D002277:Carcinoma / Q000188:drug therapy* / Q000601:surgery*; D003131:Combined Modality Therapy / Q000379:methods*; D005762:Gastroenterology / Q000379:methods; D006801:Humans; D006979:Hyperthermia, Induced / Q000379:methods*; D007274:Injections, Intraperitoneal; D008495:Medical Oncology / Q000379:methods; D008654:Mesothelioma / Q000628:therapy; D010534:Peritoneal Neoplasms / Q000175:diagnosis / Q000188:drug therapy* / Q000453:epidemiology / Q000601:surgery*; D013274:Stomach Neoplasms / Q000628:therapy; D016896:Treatment Outcome